Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 7

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

Authors Mann K, Raskin P

Received 3 January 2014

Accepted for publication 6 May 2014

Published 24 June 2014 Volume 2014:7 Pages 229—239


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Katherine V Mann,1 Philip Raskin2

1PharmD Consulting, LLC, Royal Oak, MD, USA; 2Department of Internal Medicine, Division of Endocrinology, the University of Texas Southwestern Medical Center, Dallas, TX, USA

Background: This article reviews the clinical efficacy, safety, and patient outcomes literature on the first once weekly treatment for type 2 diabetes mellitus (T2DM), exenatide extended-release (ER).
Methods: Relevant literature on exenatide ER and T2DM was identified through PubMed database searches from inception until April 2014.
Results: Exenatide ER is the first medication for the treatment of T2DM dosed on a weekly schedule. Exenatide ER is a glucagon-like peptide-1 (GLP-1) receptor agonist, the third to be approved in the US, and is associated with a low risk of hypoglycemia, may result in weight loss, and has proven to be a safe and effective treatment for T2DM. Exenatide ER reduces A1c levels by decreasing fasting and postprandial hyperglycemia. The most common adverse events are gastrointestinal in nature, which are lesser in frequency than those observed with short-acting exenatide. Exenatide ER has been shown to be more effective than exenatide twice daily and slightly less efficacious than liraglutide. Exenatide ER is useful as monotherapy and in combination with other oral antidiabetic drugs.
Conclusion: Once weekly treatment options for diabetes such as exenatide ER have the potential to offer substantial convenience for patients who have high medication burden and poor medication adherence.

Keywords: type 2 diabetes mellitus, long-acting release, GLP-1 receptor agonists

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]